Medicine and Dentistry
Bladder Cancer
93%
Prostate Cancer
91%
Cystectomy
77%
Prostatectomy
68%
Health Care Cost
53%
Muscle Invasive Bladder Cancer
47%
Malignant Neoplasm
46%
Retroperitoneal Lymph Node Dissection
39%
Robot-Assisted Prostatectomy
38%
Non Muscle Invasive Bladder Cancer
36%
Systematic Review
31%
Odds Ratio
31%
Hazard Ratio
30%
Disease
30%
Recurrent Disease
24%
Radiation Therapy
22%
Medicare
21%
Neoplasm
21%
Clinical Stage
20%
Surgeon
20%
Chemotherapy
19%
Surgical Margin
19%
Urologist
17%
Surveillance, Epidemiology, and End Results
17%
Transitional Cell Carcinoma
17%
Pelvis
16%
Randomized Controlled Trial
15%
Quality of Life
15%
Testis Cancer
14%
Bladder
14%
Surgery
14%
Comorbidity
14%
Radical Retropubic Prostatectomy
14%
Urology
13%
Logistic Regression Analysis
12%
Overall Survival
12%
Bleeding
12%
Meta-Analysis
11%
Cost-Effectiveness Analysis
10%
Prostate Biopsy
10%
Cancer
10%
Prostate Specific Antigen
9%
Proportional Hazards Model
9%
Biopsy Technique
9%
Lymph Node
9%
Urinary System
9%
Partial Nephrectomy
9%
Prostate Hypertrophy
9%
Veterans Affairs
9%
Cancer Specific Survival
9%
Keyphrases
Bladder Cancer
100%
Radical Cystectomy
58%
Confidence Interval
54%
Radical Prostatectomy
51%
Muscle-invasive Bladder Cancer
49%
Prostate Cancer
41%
Non-muscle Invasive Bladder Cancer (NMIBC)
40%
Robot-assisted Laparoscopic Radical Prostatectomy
36%
Cancer Patients
30%
Odds Ratio
30%
Hazard Ratio
29%
Population-based
19%
High Risk
18%
Positive Surgical Margin
18%
Urologists
17%
Retroperitoneal Lymph Node Dissection (RPLND)
17%
Survival Outcomes
17%
Surveillance Epidemiology
17%
Randomized Controlled Trial
15%
Active Surveillance
15%
Robot-assisted Radical Prostatectomy
15%
Upper Tract Urothelial Carcinoma
14%
Overall Survival
13%
Equal Access
13%
United States
13%
High-grade Prostate Cancer
11%
Recurrence Rate
11%
Intermediate Risk
11%
Combined Modality Therapy
10%
Radical Retropubic Prostatectomy
10%
Oncologic
10%
Radiotherapy
10%
Cancer-specific Survival
10%
Testicular Cancer
10%
Urology
9%
Laparoscopic Partial Nephrectomy
9%
Comorbidity
9%
Radiation Therapy
9%
Length of Stay
9%
Oncological Outcomes
9%
Biochemical Recurrence
9%
African American
9%
Quality of Life Outcomes
9%
Tumor
9%
Cancer Diagnosis
9%
Risk Factors
9%
Blue Light Cystoscopy
9%
National Survey
9%
Enhanced Recovery after Surgery (ERASĀ®)
9%
Testosterone Replacement Therapy
9%